

Gentian Diagnostics announces the death of its founder Dr. Erling Sundrehagen

Moss, 10 October 2024

Gentian Diagnostics announces with deep sadness the passing of Dr. Erling Sundrehagen, the founder and a driving force behind the development of the company, on 9 October 2024.

Dr. Sundrehagen had a distinguished career in the medical, bioanalytical, and in-vitro diagnostic (IVD) sciences. He earned his cand.med. degree from the University of Oslo in 1976, and subsequently obtained a cand.real. (M.Sc.) in nuclear chemistry and related scientific fields in 1978. In 1984, he was awarded his Dr.med. degree from the same institution. Dr. Sundrehagen's clinical expertise encompassed various roles as a consultant and resident at prominent hospitals and institutions, including the Norwegian Radium Hospital. He was a pioneering figure in protein variant analysis, held numerous international patents, and received several international awards for his groundbreaking contributions.

In the mid 1980's Dr. Sundrehagen founded Axis Biochemicals which in 1999, merged with UK-based Shield Diagnostics, forming Axis-Shield, a significant international player within the IVD sector. Dr. Sundrehagen held several senior positions within these organizations before founding Gentian Diagnostics, where he played a crucial role in the company's development as its Chief Scientific Officer (CSO).

In his later years, Dr. Sundrehagen served as the Consulting Founder to Gentian Diagnostics, a role he maintained until his passing.

The Company expresses its deepest gratitude for Dr. Sundrehagen's invaluable contributions to Gentian Diagnostics and the IVD field and extend its heartfelt condolences to his family and colleagues.

IR and press contact:

Njaal Kind, CFO

njaal.kind@gentian.no

+47 919 06 525